Results 311 to 320 of about 528,168 (327)

PET/MR Imaging in Cardiovascular Imaging

PET Clinics, 2019
With the emergence of PET/MR imaging there have been some strides in replicating the cardiovascular imaging success of other hybrid imaging modalities such as PET/computed tomography (CT) and single-photon emission computed tomography/CT. Because of the combined molecular imaging capabilities of PET and high-spatial and high-contrast resolution of MR ...
Rischpler, Christoph, Woodard, Pamela K.
openaire   +3 more sources

Fundamentals of PET and PET/CT imaging

Annals of the New York Academy of Sciences, 2011
In this review, the fundamental principles of fluorodeoxyglucose (FDG) positron emission tomography (PET) and FDG PET/computed tomography (CT) imaging have been described. The basic physics of PET instrumentation, radiotracer chemistry, and the artifacts, as well as normal physiological or benign pathological variants, have been described and presented
Sandip, Basu, Thomas C, Kwee, Suleman, Surti, Esma A, Akin, Don, Yoo, Abass, Alavi   +5 more
openaire   +2 more sources

Molecular Imaging by PET

2003
Positron emission tomography (PET) allows quantitative measurements of regional physiological and biochemical processes to be made in vivo in humans. PET determines the three-dimensional distribution of activity in the organ being studied after the subject is administered a tracer labeled with a positron emitting radionuclide.
openaire   +2 more sources

Cardiac PET Imaging

PET Clinics, 2011
Wengen, Chen, Amol M, Takalkar
openaire   +2 more sources

Diagnostic Imaging: PET/CT(PET)

2020
PET (Positron-Emission Tomography) has a unique feature that is visualized “metabolic activities” of cell, or tissue. Malignant tumors including esophageal cancers usually show hypermetabolism of glucose to be depicted clearly by using FDG-PET.
openaire   +1 more source

FDG-PET and amyloid-PET imaging

Current Opinion in Neurology, 2014
The availability of PET neuroimaging tools for the in-vivo assessment of metabolic dysfunction and amyloid burden in Alzheimer's disease has opened important methodological and practical issues in the diagnostic design and the conduct of new clinical trials.
openaire   +3 more sources

PET Imaging

Japanese Journal of Radiological Technology, 2009
openaire   +2 more sources

PET Imaging

2020
D. A. Scullion, G. Cook, R. Allan, D. A. Cunningham   +3 more
openaire   +1 more source

PET Imaging of Lymphoma

PET Clinics, 2012
Rebecca L, Elstrom, Stephen J, Schuster
openaire   +2 more sources

PET Imaging

2008
Johan Vansteenkiste, Christophe Dooms, Jokke Wynants   +2 more
openaire   +1 more source